Survival data boosts Merck's Keytruda lead in lung cancer

(Reuters) – Merck & Co’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *